M. Migden, “Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3”, J of Skin, vol. 7, no. 2, p. s176, Mar. 2023.